Compounded Semaglutide vs. Ozempic: A Pharmacist's Honest Assessment

If you have spent any time researching GLP-1 medications online, you have probably seen compounded semaglutide advertised at a fraction of the cost of Ozempic. The price difference is real and significant — brand-name Ozempic runs $900 to $1,300 per month without insurance, while compounded versions from telehealth platforms are often priced at $150 to $350 per month. For many patients, that difference is the entire conversation.

As a pharmacist, I get asked about this constantly. And my honest answer is more nuanced than either the telehealth companies selling compounded semaglutide or the FDA warning letters targeting it would suggest. There are legitimate reasons a patient might choose a compounded version. There are also real risks that most of the content written about this topic — by people without a pharmacy background — gets wrong or skips entirely.

This article covers what I actually look at when a patient asks me about compounded semaglutide: the regulatory framework, the pharmacology question, the safety data, and the clinical criteria I use to evaluate whether a specific compounded product is worth considering.

What Is Compounded Semaglutide and Why Does It Exist?

Compounded semaglutide entered the US market through a specific and time-limited legal window. When the FDA places a drug on its official shortage list, licensed compounding pharmacies are permitted under federal law to prepare copies of that drug for patients. Semaglutide was added to the FDA drug shortage database in 2022 due to manufacturing constraints at Novo Nordisk that could not meet the surge in demand following the approval of Wegovy for obesity.

That shortage designation opened the door for compounding pharmacies — both 503A and 503B facilities — to legally prepare semaglutide for patients. At its peak, hundreds of compounding pharmacies and telehealth platforms were offering compounded semaglutide nationally.

The FDA shortage status for semaglutide has since changed. As of early 2025, the FDA declared the shortage resolved for both Ozempic and Wegovy, which triggered a phased wind-down period for compounded semaglutide. 503B outsourcing facilities were given a deadline to cease production, and 503A pharmacies are restricted to patient-specific prescriptions only. This regulatory landscape is actively evolving — which is one of the first things a patient should understand before starting compounded semaglutide today.

The 503A versus 503B distinction matters more than most patients realize. A 503A pharmacy is a traditional compounding pharmacy that prepares medications for individual patients based on a specific prescription. They operate under state pharmacy board oversight primarily, with limited direct FDA inspection. A 503B outsourcing facility is a larger-scale operation that operates under current Good Manufacturing Practice (cGMP) standards — the same quality standards applied to pharmaceutical manufacturers. They are subject to FDA inspection, must meet sterility and potency testing requirements, and produce medications in bulk without requiring patient-specific prescriptions.

When a telehealth platform sends you compounded semaglutide, knowing whether it came from a 503A or 503B facility is the first and most important quality question you can ask.

The FDA’s Actual Position — What It Says and What It Doesn’t

There is a significant gap between what the FDA has actually said about compounded semaglutide and how those statements have been reported. Understanding the difference matters if you are trying to make an informed decision.

What the FDA has explicitly stated:

The FDA has issued warning letters to specific compounding facilities for violations including labeling errors, failure to meet sterility requirements, and use of semaglutide salt forms (sodium and acetate salts) rather than semaglutide base. The FDA has stated that semaglutide sodium and semaglutide acetate are not the same as semaglutide — the active ingredient in Ozempic and Wegovy — and that products using these salt forms may not be legally compounded under the shortage exemption.

The FDA has also issued consumer alerts warning patients about adverse events associated with compounded semaglutide — primarily dosing errors related to the concentration variability between compounded products and brand-name semaglutide.

What the FDA has not said:

The FDA has not declared that all compounded semaglutide is unsafe or ineffective. The warning letters and alerts target specific violations and specific product types — not compounding categorically. A compounded semaglutide product using semaglutide base (not a salt form), prepared by a 503B facility operating under cGMP standards, with appropriate potency and sterility testing, occupies a meaningfully different risk category than a product from an unverified 503A pharmacy using a salt form.

The nuance matters because it gives patients a framework for evaluation rather than a binary safe-or-dangerous conclusion.

The Pharmacology Question — Is It Actually the Same Drug?

This is the section most health content gets wrong — either by oversimplifying it or by avoiding it entirely because it requires a clinical background to explain accurately.

Bioequivalence and Why It Matters Here

When a brand-name drug goes off patent and a generic version enters the market, the generic manufacturer must demonstrate bioequivalence to the FDA — meaning the generic product delivers the same active ingredient to the bloodstream at the same rate and to the same extent as the original. This is a regulatory requirement, not an assumption. Generic drugs are not assumed to be equivalent — they must prove it.

Compounded semaglutide has never undergone bioequivalence testing. This is not a criticism of compounding — it reflects the nature of the regulatory framework for compounded medications, which are not subject to the same pre-market approval requirements as generic drugs. But it does mean that the assumption of equivalence between compounded semaglutide and Ozempic is exactly that — an assumption. A reasonable one in many cases, but an assumption nonetheless.

The Salt Form Issue

This is the most clinically significant pharmacology concern with compounded semaglutide and the one most frequently overlooked in consumer-facing content.

Ozempic and Wegovy both use semaglutide in its base form — the active pharmaceutical ingredient that has been studied in clinical trials, FDA-approved, and whose pharmacokinetics (absorption, distribution, metabolism, elimination) are well characterized. Many compounded semaglutide products use semaglutide sodium or semaglutide acetate — salt forms of the molecule.

Salt forms of active pharmaceutical ingredients are not pharmacologically equivalent to the parent molecule by default. Salt form affects solubility, stability, absorption rate, and bioavailability. For some drugs the differences are negligible. For others they are clinically significant. For semaglutide specifically — there is no published pharmacokinetic data comparing semaglutide sodium or acetate to semaglutide base in humans. We do not know whether they behave equivalently in the body because the studies have not been done.

The FDA’s position is that semaglutide sodium and semaglutide acetate are not the same drug substance as semaglutide, which is why warning letters have targeted compounders using these forms. A compounded product using semaglutide base — the same molecule in Ozempic — is on firmer ground pharmacologically, though still without bioequivalence data.

What to ask your compounder: Request documentation of which form of semaglutide they use. If they cannot tell you, or if the answer is a salt form, that is meaningful clinical information.

Excipients and Formulation

Beyond the active ingredient, Ozempic’s formulation includes specific excipients — inactive ingredients that affect stability, injection tolerability, and drug delivery. Compounded formulations vary in their excipient composition. Some compounders add ingredients such as vitamin B12, L-carnitine, or NAD+ to their semaglutide formulations — often as a marketing differentiation rather than based on clinical evidence. There is no published data supporting the addition of these ingredients to semaglutide, and their effect on the pharmacokinetics of the active ingredient is unknown.

If your compounded semaglutide contains additional ingredients beyond the active pharmaceutical ingredient and a standard vehicle, ask specifically why those ingredients are included and what evidence supports their addition.

The Safety Question — What Does the Evidence Actually Show?

The FDA’s MedWatch database contains hundreds of adverse event reports associated with compounded semaglutide. Reviewing these reports as a pharmacist, the pattern that emerges is instructive.

The majority of serious adverse events appear to be related to dosing errors rather than intrinsic formulation problems. This distinction matters clinically. Brand-name Ozempic comes in pre-filled pens with fixed dose increments — 0.25 mg, 0.5 mg, 1 mg, 2 mg — making dosing straightforward. Compounded semaglutide is typically supplied as a multi-dose vial that the patient draws up with a syringe. The concentration of compounded semaglutide varies between suppliers — some are 1 mg/mL, others are 2.5 mg/mL, 5 mg/mL, or higher. A patient accustomed to one concentration who switches to a higher concentration product can inadvertently administer a significantly higher dose than intended.

This is a systems problem as much as a product problem — and it is solvable with proper patient education. But it requires that the prescribing platform actually provides that education, which not all telehealth companies do adequately.

Contamination and sterility concerns have been cited in FDA warning letters to specific compounders. Injectable medications that are not prepared under appropriate sterile conditions create real infection risk. This is another area where the 503B versus 503A distinction matters — 503B facilities have mandatory sterility testing requirements that 503A pharmacies do not.

The Cost Reality — Who Does the Math Actually Favor?

The price difference between compounded and brand-name semaglutide is real and substantial. But the full cost comparison requires looking at what is included in each option.

	Brand-Name	Compounded
Medication cost/month	$900–$1,300 (Ozempic)	$150–$350
Platform/consultation fee	—	$75–$150/month
With diabetes insurance	Often $25–$50 copay	Not covered
Patient assistance (qualifying)	Free or near-free	N/A
Realistic total	$25–$1,300	$250–$500

The gap is still significant — but narrower than the medication price alone suggests. And for patients who qualify for Novo Nordisk’s patient assistance programs, brand-name Ozempic may be available at little or no cost. Before choosing compounded semaglutide on cost grounds alone, verifying insurance coverage and manufacturer assistance program eligibility is worth the 20 minutes it takes.

Who Should Consider Compounded Semaglutide — And Who Shouldn’t

Based on the clinical evidence and the regulatory framework, here is the framework I apply when counseling patients on this question.

Compounded semaglutide may be a reasonable option for:

• Patients who do not have insurance coverage for brand-name semaglutide and do not qualify for manufacturer assistance programs
• Patients working with a physician who is actively monitoring them — baseline metabolic labs, regular follow-up, dose adjustment based on response and tolerability
• Patients sourcing from a verified 503B outsourcing facility using semaglutide base (not a salt form)
• Patients who have been counseled on proper injection technique and the specific concentration of their formulation

Patients who should be cautious:

• Patients using telehealth platforms that do not require baseline labs or follow-up visits — a prescriber who will send semaglutide to anyone who completes an online questionnaire is not providing adequate clinical oversight
• Patients whose compounded formulation contains additional ingredients (B12, L-carnitine, etc.) without a clear clinical rationale
• Patients who are self-adjusting doses without clinical guidance

Patients who should avoid compounded semaglutide:

• Anyone sourcing from a compounder who cannot verify their 503A or 503B status and provide a Certificate of Analysis for potency and sterility testing
• Patients with a history of medullary thyroid carcinoma or MEN2 syndrome — the contraindication language from the brand-name prescribing information applies regardless of formulation
• Patients on medications with significant GLP-1 interaction potential who have not had a pharmacist medication review

Seven Questions to Ask Before Starting Compounded Semaglutide

If you are considering compounded semaglutide, these are the minimum questions to get answered before your first dose:

1. Is your compounding pharmacy a 503A or 503B facility? Ask for their FDA registration number if they claim 503B status — it is publicly verifiable at fda.gov.
2. What form of semaglutide do you use — base, sodium, or acetate? The answer should be semaglutide base.
3. What is the concentration of this formulation in mg/mL? You need this to calculate your dose correctly.
4. Can you provide a Certificate of Analysis for potency and sterility? A legitimate compounder will have this for every batch.
5. Does your formulation contain any additional ingredients? If yes, ask specifically what they are and why they are included.
6. What monitoring is included in your program? Baseline labs, follow-up visits, and dose adjustment guidance should be standard.
7. What is your protocol if I experience a serious adverse event? You should have a clear answer and a clinical contact — not just a customer service email.

If a telehealth platform cannot answer these questions clearly and completely, that tells you something important about the quality of clinical oversight you will receive.